Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (41-50 of 247) with videos related to

Pageof 25
Sort By:
Oncotarget|September 1, 2018
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumorsJordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, et al.
The Oncologist|August 22, 2014
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinomaJoaquim Bellmunt, Cristina Suarez, Enrique Gallardo, et al.
Oncology Letters|July 3, 2015
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrateJuan Sepulveda-Sanchez, Ana Ramos, Amaya Hilario, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2015
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R Brown, Matthew S Davids, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal MalignanciesKhaldoun Almhanna, Thea Kalebic, Cristina Cruz, et al.
JCO Precision Oncology|April 5, 2024
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case ReportCamilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaDevalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, et al.
Immunotherapy|September 9, 2020
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulinsJosé María Díez, Carolina Romero, Júlia Vergara-Alert, et al.
Emerging Microbes & Infections|November 13, 2019
Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike proteinJordi Rodon, Nisreen M A Okba, Nigeer Te, et al.
Drugs in Context|December 20, 2016
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancerIvelina Gueorguieva, Ann Cleverly, Durisala Desaiah, et al.
Pageof 25

Showing results (41-50 of 247) with videos related to

Sort By:
Pageof 25
Oncotarget|September 1, 2018
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumorsJordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, et al.
The Oncologist|August 22, 2014
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinomaJoaquim Bellmunt, Cristina Suarez, Enrique Gallardo, et al.
Oncology Letters|July 3, 2015
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrateJuan Sepulveda-Sanchez, Ana Ramos, Amaya Hilario, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2015
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R Brown, Matthew S Davids, Jordi Rodon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal MalignanciesKhaldoun Almhanna, Thea Kalebic, Cristina Cruz, et al.
JCO Precision Oncology|April 5, 2024
First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case ReportCamilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaDevalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, et al.
Immunotherapy|September 9, 2020
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulinsJosé María Díez, Carolina Romero, Júlia Vergara-Alert, et al.
Emerging Microbes & Infections|November 13, 2019
Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike proteinJordi Rodon, Nisreen M A Okba, Nigeer Te, et al.
Drugs in Context|December 20, 2016
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancerIvelina Gueorguieva, Ann Cleverly, Durisala Desaiah, et al.
Pageof 25